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The advent of next generation sequencing has facilitated the establishment of an 
exhaustive catalog of recurrent mutations in Acute Myeloid Leukemia (AML). We know that 
FLT3 is the most commonly mutated gene in the disease, it is activated most commonly through 
internal tandem duplication (ITD) within the juxtamembrane domain, and at a lesser frequency 
via point mutations in the kinase domain. Flt3ITD/+ knock-in mice develop a fatal 
myeloproliferative neoplasm (MPN) but fail to fully transform, indicating that additional 
mutations are necessary for leukemogenesis. Genetically engineered mouse strains provide a 
powerful platform to investigate what these cooperating mutations might be, and identify 
signaling differences in these mice. 
While ITD and mutations within the kinase domain (most commonly D835Y) both 
constitutively activate the kinase, these mutations confer distinct prognoses and signaling 
differences according to survival analyses and in vitro studies, respectively. In addition to our 
Flt3ITD/+ model, we generated a Flt3D835Y/+ knock-in and observed several differences between 
the two mutant strains, including differences in the stem cell compartments and disease spectra.  
As in human subjects, Flt3D835Y/+ conferred a more indolent disease with longer median survival 
than Flt3ITD/+. Additionally, in agreement with previous in vitro studies Stat5 was preferentially 
phosphorylated in progenitor cells from Flt3ITD/+ bone marrow compared with Flt3D835Y/+.  To 
further characterize signaling difference between these genotypes, we performed expression 
arrays using progenitor cells from each genotype, and identified a number of differentially 





As previously stated, studies in Flt3ITD/+ mice suggest that additional mutations are 
necessary for transformation.  Pairwise comparisons of large datasets have identified a number of 
potentially cooperating mutations, including DNMT3A and FLT3-ITD, which co-occur in a 
significant proportion of patients, portending a poor prognosis. We examined the potential 
cooperativity by breeding a substrain of our Flt3ITD/+ mice with a conditional knock-out of 
Dnmt3a and find that the two mutations do, indeed cooperate to drive leukemia development, 
expansion of multiple progenitor pools, and enhanced self-renewal.  Interestingly, we found that 
Dnmt3a dosage significantly affected a number of these parameters, indicating the importance of 
Dnmt3a stoichiometry in hematopoiesis, and transformation in the context of Flt3ITD/+. 
 Among DNMT3Amut;FLT3-ITD patients, it was recently discovered that a significant 
subset of these patients also harbor a mutant NPM1 allele (NPM1c+).  We hypothesized that the 
addition of a mutant Nucleophosmin to our Flt3ITD/+;Dnmt3af/f  model might lead to a more 
aggressive and uniform disease, since patients with all three mutations cluster together based on 
a number of other molecular parameters.  While data is very preliminary, we find that the 
additional of NPMc+ doesn’t shorten survival, but increases disease aggressiveness, with a larger 
percentage of blasts in the bone marrow at the time of sacrifice.   
This work underscores the power and utility in discerning functionally characterizing 
mutations relevant to human disease.  Using isogenic mouse strains, we have begun to elucidate 
signaling differences underlying various activating FLT3 mutations, demonstrated for the first 
time that mutant DNMT3A and FLT3 cooperate to drive leukemia development, and the addition 
of mutant NPMc+ enhances disease severity.  Taken together, these mice can be used a powerful 
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1. CHAPTER 1. INTRODUCTION 
 
1.1 Overview of AML 
Acute Myeloid Leukemia (AML) is an aggressive neoplastic condition, leading to 
accumulation of immature myeloid cells and ineffective hematopoiesis. In 2014, the American 
Cancer Society projected around 19,000 newly diagnosed Acute Myeloid Leukemia (AML) 
cases, and around 11,000 deaths. AML arises when mutations occur in a primitive progenitor cell 
within the bone marrow niche, which are then propagated to the cellular progeny. Additional 
genetic changes are acquired, conferring a selective advantage to these cells, and subsequent 
clonal outgrowth of immature, abnormally functioning, rapidly dividing stem cells. This step 
wise genetic progression of cancer development was first proposed by Peter Nowell 
(Nowell,P.C. 1976), however thorough investigation and identification of what these mutations 
might be wouldn't be feasible until decades later, with the introduction of next generation 
sequencing (Bentley,D.R. 2008).   
Over the last several decades, the WHO and FAB classifications of leukemia subtypes 
were descriptive, relying on morphological changes to classify patients. The advent and 
affordability of whole genome sequencing, (WGS) presented an opportunity to completely 
annotate the leukemia genome, identifying a number of genetic perturbations (sequence variants, 
expression differences and methylation changes) that might correlate with clinical outcomes and 
aid in the understanding of disease pathogenesis. With an extensive list of mutations, we have 
identified particular mutations, including internal tandem duplications within FLT3 (FLT3-ITD), 




mutations through in vitro and in vivo studies is essential in identifying new, effective 
therapeutic targets.  
1.2 FLT3 in normal hematopoiesis  
FLT3 is a receptor tyrosine kinase, which is expressed in the earlies stages of 
hematopoiesis, and is turned off during differentiation in a lineage specific manner 
(Matthews,W. 1991). Expression of FLT3 is essential to maintaining healthy hematopoeisis, as 
targeted disruption of the gene results in defective stem cell engraftment and B cell progenitor 
defects in the bone marrow (Mackarehtschian,K. 1995). In development of lymphoid cells, FLT3 
is expressed in common lymphoid progenitors (CLP), but is shut off during later points of 
lymphocyte development. FLT3 expression in myeloid cells is restricted to a smaller population 
wtihin the common myeloid progenitor (CMP) compartment, but is extremely important in 
facilitating dendridic cell development (63 D'Amico,A. 2003).  
Normally, FLT3 is stimulated by its ligand, cuing the cell to grow by activating multiple 
downstream signaling pathways including MAPK and PI3K. This stimulation drives cells to 
rapidly divide and differentiate into more restricted progenitors, predominantly cells within the 
myeloid lineage. Knock-out of the ligand (Flt3-L) in mice results in even more severe defects 
than Flt3 deletion, underscoring the importance of FLT3 in normal blood development 
(McKenna,H.J. 2000). 
1.3 The role of FLT3 and FLT3 mutations in AML 
FLT3 is now recognized as the most frequently mutated gene in AML, where activating 
mutations in either the juxtamembrane or kinase domain of the protein predict distinct clinical 
outcomes. About 25% of AML patients harbor an internal tandem duplication within the 




(Shen,Y. 2011). These in-frame mutations vary in size, from 9-300 base pairs, and lead to ligand 
independent activation of downstream oncogenic pathways, including MAPK and PI3K. 
Additionally, phosphorylated STAT5 seems to be particularly prominent in this context, 
suggesting this transcription factor is important in the disease. Less commonly, point mutations 
occur in the kinase domain (most often D835Y), and predict a more favorable prognosis than the 
FLT3-ITD.  
Given the mutation frequency and poor prognosis associated with FLT3-ITD, our lab 
previously sought to understand if this mutation alone was sufficient to drive leukemia 
development using a knock-in mouse model (Li,L. 2008).  Flt3ITD/+ mice succumb to a fatal 
myeloproliferative neoplasm (MPN) with a median survival of around 350 days but failed to 
develop AML, suggesting additional cooperating mutations are necessary to drive 
leukemogenesis. 
Subsequent studies in these mice have revealed potential underlying roles of Flt3-ITD in 
leukemogenesis, including defective DNA repair and stem cell abnormalities.  For example, 
knock-in of the same Flt3-ITD mutation results in a block in differentiation of the B cell lineage, 
as Pro-B cells exhibit increased double strand breaks induced by VDJ recombination machinery, 
but ineffective repair via non-homologous end joining (NHEJ) (Li,L. 2011). This leads to a 
reduction in the number of B cells and a block in differentiation. These findings have important 
implications about the contribution of FLT3-ITD to leukemia development, as these mutations 
may compromise the integrity of the genome within the bone marrow. Murine studies have also 
implicated FLT3 as a critical regulator of quiescence, as knock-in of the ITD mutation leads to 




quiescence, driving cells to proliferate and differentiation toward a myeloid fate (Small,D. 1994; 
Chu,S.H. 2012).  
1.4 Sequencing efforts to identify cooperating mutations 
The commercial availability of next generation sequencing in 2008 enabled researchers 
all over the world to sequence tumor samples in a high throughput manner. By sequencing whole 
genomes and exomes of leukemic and matched normal samples, we were suddenly able to 
extensively catalog and annotate the leukemia genome. These studies yielded important findings 
regarding the frequency of each mutation among AML patients, and established 8-13 as the 
median number of mutations in a given leukemia, which is decidedly lower than most other solid 
tumors (Vogelstein,B. 2013). 
Given that numerous mutations are present within a typical AML sample, it is not 
surprising that while FLT3 mutations are the most frequent, commonly FLT3-ITD (16 Cancer 
Genome Atlas Research Network 2013; 15 Welch,J.S. 2012), these mutations are insufficient to 
alone cause leukemia in murine models and likely require additional genetic events to fully 
transform ( Li,L. 2008; Bailey,E. 2013). Using the wealth of whole genome sequencing data, we 
can determine which mutations are concurrently mutated to hypothesize what these cooperating 
events might be. 
In a 2012 study, Patel et al. performed targeted sequencing on a cohort of 400 AML 
patients, examining fifty of the most frequently mutated genes (Patel,J.P. 2012). By performing 
pairwise comparisons, they determined which genes were commonly co-mutated in patients. 
Once again, FLT3 was established as the most frequently mutated gene, and these patients also 
harbored concomitant DNMT3A mutations. Additionally, when stratifying patients by FLT3-ITD 




compared with other genotypes, underscoring the likelihood that mutant FLT3 and DNMT3A 
represent synergistic and cooperating mutational events in leukemia. 
 
1.5 DNMT3A in stem cell function and transformation  
Beyond changes to the DNA sequence, epigenetic modifications, including DNA 
methylation and histone modifications, have long been established as important regulators of 
gene expression and function. DNA methyltransferases covalently link methyl groups to 
cytosines (or adenines) to control gene expression via two different mechanisms. Maintenance 
methyltransferases, such as DNMT1, ensure stable transmission of methylation from a dividing 
cell to the resulting daughter cells. De novo methyltransferases, including DNMT3A and 
DNMT3B, produce labile modifications to the DNA, responding to environmental cues to 
methylate novel loci, controlling gene expression as necessary. Recent Crispr/Cas9 disruption of 
DNMT1 in human embryonic stem cells resulted in rapid cell death, while mutating DNMT3A 
and/or DNMT3B resulted in global hypomethylation, but less severe cellular defects (Liao,J. 
2015). In the hematopoietic system, conditional knock-out of Dnmt1 in the stem cell 
compartment leads to stem cell depletion, cell cycle abnormalities, and defects in self-renewal 
(Trowbridge,J.J. 2009). Conversely, conditional ablation of Dnmt3a in murine bone marrow 
results in expansion of the long term hematopoietic stecm cell (LT-HSC) pool through enhanced 
self-renewal (Challen,G.A. 2011). These opposing phenotypes indicate that DNMT1 and 
DNMT3A play distinct functions in the hematopoietic system. These experiments provide a 
biological basis for the preponderance of mutations in DNMT3A, and near absense of DNMT1  




DNMT3A, like FLT3, is one of the most frequently mutated genes in AML. Missense 
mutations in DNMT3A are nearly always heterozygous in this context, often occuring in the 
methyltransferase domain. Within this hot spot, an amino acid substitution altering Arginine 882 
to Histidine is most common, and several lines of evidence suggest these heterozygous 
alterations result in a dominant negative loss of function (Zhang,J. 2012; Walter,M.J. 2011; 
Tadokoro,Y. 2007; Holz-Schietinger,C. 2012). In vitro experiments have shown the R882H 
mutation significantly inhibits tertramerization, and processive methylation of promoters (Holz-
Schietinger,C. 2012; Kim,S.J. 2013). These findings were corroborated when Tim Ley's group 
mined the TCGA data set, finding R882H mutant patient samples exhibited significant global 
hypomethylation, and again, resulted in ineffective tetramer formation (Russler-Germain,D.A. 
2014). Ideally, a mouse harboring a heterozygous mutation knocked into the orthologous residue 
(R878H) would present the ideal tool to rigorously perform in vivo experiments, no such model 
is currently available. Given the overwhelming evidence that the common R882H mutation 
results in a dominant negative loss of function, conditionally knocking out Dnmt3a in a bone 
marrow specific manner presents the best approach to biologically model these mutations. 
Extensive work using inducible, hematopoietic specific knock-out of Dnmt3a has defined 
the gene as essential in regulating self-renewal, as its deletion results in significant expansion of 
LT-HSCs (Challen,G.A. 2011). Global methylation analysis of LT-HSCs revealed that Dnmt3a 
loss resulted in hypomethylation and increased expression of important genes known to maintain 
stemness. These genes failed to be appropriately methylated in downstream, differentiated 
progeny, where this stem cell signature continued to be aberrantly expressed. Upon further 
analysis of these data, it became clear that the genomes of LT-HSCs is partitioned into larger 




and concomitant H3K27 trimethylation (Jeong,M. 2014). Dnmt3a deletion often led to expansion 
of these canyons, often containing stem cell related genes, indicating that Dnmt3a is important in 
maintaining appropriate expression of these genes through site specific CpG methylation, as well 
as maintaing appropriate methylation at canyon borders. Loss of these methylation patterns 
therefore leads to uncontrolled expression of these genes, enhanced stem cell self-renewal, and 
expansion of this progenitor pool.  
In a study similar to the one we previously performed with our Flt3-ITD knock-in model, 
these Dnmt3a conditional knock-out mice (Dnmt3af/f ) were watched over time for disease 
development to assess the ability for Dnmt3a deletion alone to cause leukemia (Mayle,A. 2014). 
Unlike our Flt3-ITD mice, which solely develop MPN, developed a spectrum of neoplasms, 
including AML, T-ALL, and preleukemic conditions. However, median survival was around 300 
days, which is significantly long for a mouse model of leukemia. We hypothesized that breeding 
this model with our Flt3-ITD knock-in, representing two of the most frequently co-mutated 
genes in AML, would cooperate to shorten survival and drive AML development, thus 
mimicking human disease. 
1.6 NPM1 as a potential cooperating event 
Along with DNMT3A and FLT3, NPM1 (Nucleophosmin) is among the most frequently 
mutated genes in AML, and occurs at a similar frequency (Patel,J.P. 2012). As a nucleolar 
protein, NPM1 normally shuttle between the nucleus and cytoplasm to exert a number of critical 
cellular functions, including ribosomal biogenesis, controlling cell growth through 
transcriptional regulation, and maintaining genomic stability (Grisendi,S. 2006). In the setting of 
normal karyotype AML (NK-AML), NPM1 mutations are heterozygous.  Referred to as NPMc+, 




and replace it with a novel nuclear export motif (66 Falini 2006). Abnormal nuclear export leads 
to accumulation of the protein in the cytoplasm resulting in failed p53-dependent cell cycle arrest 
due to the inability of mutant NPM1 to interact with p19Arf  (Falini,B. 2009). 
Several transgenic mouse models have been generated to study NPMc+ function, but the 
model discussed in chapter 4 harbors a mutant NPMc+ transgene driven by the human, myeloid 
specific promoter MRP8 (hMRP8-NPMc+) (69 Cheng,K. 2010). Characterization of these mice 
found, yet again, that while these mutations are common in AML, they alone appear to be 
insufficient to result in full blown leukemia, as these mice succumb to a fatal MPN with 
incomplete penetrance. As NPMc+ mutations occur with the FLT3-ITD mutation at an 
appreciable frequency, and their co-occurrence is a poor prognostic indicator (Meyer,S.C. 2014), 
Flt3ITD/+ mice were bred with the (hMRP8-NPMc+) model and followed for survival (8 Rau 
2014). These mutations did indeed cooperate to generate myriad neoplasms, including AML, 
MPN, and T-ALL, however the median survival was extremely long at 420 days. As previously 
mentioned, the median number of mutations in an AML sample is between 8-13, indicating that 
additional cooperating mutations may be necessary to accelerate the disease in the murine 
setting. 
A recent TCGA publication identified a unique patient population harboring mutations in 
DNMT3A, FLT3, and NPMc+ concurrently, exhibiting common clinical features (16 Cancer 
Genome Atlas Research Network 2013).  Breeding the hMRP8-NPMc+ onto the 
Flt3ITD/+;Dnmt3af/f background presents the an opportunity to study the potential cooperativity of 





2.  CHAPTER 2. KNOCK-IN OF SPECIFIC FLT3 MUTATIONS IN MICE 
FACILITATES STUDY OF SIGNALING DIFFERENCES 
 
2.1 Introduction 
FLT3 is well established as the most frequently mutated gene in AML, with two 
predominant classes of mutations constitutively activating the kinase (Patel,J.P. 2012; 
Meshinchi,S. 2009; Cancer Genome Atlas Research Network 2013). Internal tandem 
duplications of the juxtamembrane domain (FLT3-ITD) are more common, occuring in 25% of 
patients, portending a worse prognosis than point mutations in the kinase domain (FLT3-KD), 
which are less common, occurring in 10% of patients. FLT3-ITD mutations induce ligand 
independent of downstream pathways PI3K, RAS, ERK, as well as enhanced STAT5 
phosphorylation. FLT3-KD mutants activate the same signaling cascades, however STAT5 is 
only weakly activated, indicating distinct pathways are important for disease development, 
which may also account for differing prognoses between the two mutations (Meshinchi,S. 2009). 
Our lab previously generated a Flt3ITD/+ knock-in harboring an 18 base pair ITD cloned 
from a patient. These mice developed a fatal MPN with a median survival of 400 days. To assess 
the effects of FLT3-KD in vivo in a similar manner, the lab generated a knock-in of the most 
common mutation D835Y (the orthologous mouse residue is D838, which was altered to D838Y, 
but these mice will be referred to as Flt3D835Y/+ for simplicity's sake) (Bailey,E. 2013). Similar to 
the Flt3ITD/+ model, the D835Y mutation alone was insufficient to leukemia development, as 
these mice developed MPN, histiocytic sarcomas, and B and T cell lymphomas. Of note, median 
survival for Flt3D835Y/+ mice was 678 days, vs. 394 days in the Flt3D835Y/+ mice. Additionally, 




prominent in the Flt3D835Y/+ mice compared with Flt3ITD/+. The extended survival and attenuated 
Stat5 phosphorylation seen in Flt3D835Y/+ mice mimics phenotypic differences seen in patients 
with FLT3-KD and FLT3-ITD mutations, indicating that these mouse models present a powerful 
tool to assess the diverging signaling pathways responsible for eliciting these differences.  
 
2.2 Results 
2.2.1 Expression array identifies differentially expressed genes in Flt3ITD/+ and Flt3D835Y/+ 
progenitors  
The MouseWG-6 v2.0 Microarray allowed us to analyze over 45,200 transcripts 
simultaneously in LSK cells from wild type,  Flt3ITD/+, and Flt3D835Y/+  mice at an early time 
point, prior to disease presentation in Flt3ITD/+ mice. After normalizing the data, hierarchical 
clustering was performed to determine similarities between individual samples. As expected, 
biological replicates from each genotype clustered with eachother (figure 2-1A). Initially, 4 
samples per genotype were included in the study. Initial hierarchical clustering aligned one of the 
Flt3-ITD samples in the wild type cluster. The outlying samples was therefore excluded, leaving 
only 3 biological replicates from Flt3ITD/+ mice for analysis.  Additionally, wild type and D835Y 
samples are members of the same bifurcating arm on the dendogram, while ITD samples are 
separated to the left. These results indicate that expression patterns separate ITD samples from 
both other genotypes, while D835Y and wild type samples were more similar to eachother.   
 After hierarchical clustering, a Benjamini-Hochberg correction was used to derive 
adjusted p values, and identified 1301 probes in D835Y samples and 1471 probes in ITD 
samples were differentially expressed compared to wild type mice.  To reduce the number of 




value of less than 0.05. Establishing these cut offs identified 185 genes overall that were 
differentially expressed over both Flt3 mutant genotypes (figure 2-1B). In keeping with the 
hierarchical clustering data, these thresholds identified more differentially expressed genes in the 
ITD samples than the D835Y samples; 162 genes vs 45 genes respectively (figure 2-1C).  22 of 
these genes were differentially expressed in both mutant populations, and just one of these genes, 
Dntt,  was reciprocally expressed as it was upregulated in D835Y and downregulated in ITD 
compared to wild type (figure 2-1D).     
2.2.2 Validation of candidate genes in murine progenitors by qPCR 
 To confirm the Dntt expression patterns identified in the microarray, we performed qPCR 
on lineage negative bone marrow from each genotype, using mice ranging in age from 6 to 20 
weeks. At each time point, expression patterns in qPCR experiments validated the dysregulation 
seen in the array (figure 2-2). By expanding the threshold to include any reciprocally expressed 
gene above log2 fold change of 0.5 (absolute fold change ~1.41) we identified (X) number of 
differentially expressed genes, (X) of which were reciprocally expressed. We additionally 
validated two of these genes (Gata2 and Kdm7a) in the same manner as with Dntt, and 
corroborated the findings from the microarray, with Kdm7a being overexpessed in D835Y and 
underexpressed in ITD samples compared to wild type, and Gata2 being downregulated in both 
genotypes.  
 One gene in particular seemed to display the predicted reciprocal expression in an age 
dependent manner. The results from the microarray predict Cox6a2 to be upregulated in D835Y 
and downregulated in ITD samples. Reciprocal expression isn't observed until 20 weeks of age 
(figure 2-3A). This progressive dysregulated expression of Cox6a2 may represent an important 




down regulation occurs in ITD samples at 20 weeks of age, a time point more similar to the time 
point assayed in the microarray.    
 To assess protein levels of Cox6a2 between genotypes, we performed western blotting on 
protein samples from Ba/F3 cells transduced with human wild type FLT3, FLT3-D835Y, or 
FLT3-ITD overexpression constructs (figure 2-3B). While Cox6a2 protein levels failed to exhibit 
lower levels in FLT3-ITD expressing cells compared with wild type FLT3 expressing cells, 
protein expression is extremely elevated in FLT3-D835Y cells, in agreement with the array 
results. The failure of protein expression to be depressed in FLT3-ITD cells may reflect the 
nature of the cell line used. Ba/F3 cells are a lymphoid cell line, and the expression data was 
derived from primary mouse progenitor cells. To examine this possibility, we performed western 
blot experiments to detect Cox6a2 protein in lineage negative cells from 6 week old mice (figure 
2-3C). While protein expression was lower in cells from Flt3ITD/+ mice compared with Flt3D835Y/+ 
samples, the lack of a wild type control here makes it difficult to draw comparisons relative to 
the normal progenitor population. Additionally, 20 week old mice were not available at the time 
this experiment was performed. Given that qPCR validation at this later time point more closely 
resembled the microarray expression levels, future experiments in primary cells should be 
performed in that later time point. 
 We hypothesized that since Cox6a2 is a protein expressed in the mitochondrial as one of 
the most terminal enzymes in the electron transport chain, we hypothesized perhaps the 
downregulation of Cox6a2 seen in Flt3ITD/+ mice may lead to uncoupling of the electron 
transport chain, disrupted membrane potential, and increased ROS production, as the ITD 
mutation has been associated with increased reactrive oxygen species previously (Sallmyr,A. 




weeks of age with a cell-permeant dye that fails to fluoresce in its reduced state, but once 
oxidized by ROS, exhibits bright fluorescence. After incubation, flow cytometry revealed 
extremely high fluorescence levels in Lin- cells from Flt3ITD/+ mice, and no real difference 
between wild type and Flt3D835Y/+ samples (figure 2-3D). ROS levels assessed at earlier time 
points were marginally increased in both Flt3 mutant genotypes compared to wild type (figure 2-
3E). The exaggerated ROS production at 20 weeks specifically correlated with depressed 
Cox6a2 in the microarray, and qPCR experiments from ITD mice at this time point, indicating 
that dysregulation of this mitochondrial protein may be playing a role. Further experiments are 
necessary to define a causative role. 
2.3 Discussion 
Discovering the causative signaling differences in which dictate differing clinical 
outcomes in FLT3-ITD and FLT3-TK mutated AMLs is important in providing insight into 
disease development, and subsequently informs targetable pathways to more effectively treat the 
disease. Our knock-in mice of each mutation recapitulate the survival variations and signaling 
differences seen in patients, including variable STAT5 phosphorylation. Performing expression 
analysis within the progenitor compartments in these mice presents a genetically pure system to 
investigate the contribution of each mutation to downstream signaling activation.  
The attenuated phenotype in the Flt3D835Y/+ mice correlated with expression findings, as 
expression patterns were more similar to wild type mice compared Flt3ITD/+ mice. When 
considering all differentially expressed genes reaching statistical significance and a log fold 
change of 2, Dntt, otherwise known at Tdt, was upregulated in LSK cells from Flt3D835Y/+  mice, 
and downregulated in Flt3ITD/+ samples. This specialized polymerase is expressed in immature B 




in these cell populations (Mahajan,K.N. 1999; Mahajan,K.N. 2002). The overexpression of this 
gene in Flt3D835Y/+ progenitors may account for the T and B lymphomas that develop in these 
knock-in mice. Conversely, repressed Dntt expression in Flt3ITD/+ may be responsible for solely 
driving these mice toward a myeloid fate, and provide a mechanism for the defective NHEJ 
observed in these mice (Li,L. 2011).  We attempted to perform intracellular staining and flow 
cytometry to correlate protein expression with mRNA levels, however these experiments are 
difficult to perform, and presented a number of challenges. Optimization of the protocol, and/or 
western blotting for the protein will be necessary to further confirm the microarray results. 
Unlike Dntt, which was exhibited similarly dysregulated expression levels at each time 
point assayed from primary mouse cells, Cox6a2 exhibited dysregulation most similar to 
microarray experiments at 20 weeks of age. Since 12-16 week old mice were used for the initial 
microarray experiments, the 20 week time point more accurately represents the primary data we 
are attempting to validate. Decreased expression in the Flt3ITD/+ mice may lead to increased ROS 
production in these mice, as inhibited COX protein expression is associated dissipation in 
mitrochondrial membrane potential, oxidative stress and dysfunction, and resultant ROS 
production (Lecoeur,H. 2012). Knockdown and overexpression experiments in these cells will be 
necessary to begin linking Cox6a2 expression to ROS production. 
 
2.4 Conclusions 
The data presented in this chapter begins to reveal expression differences between 
Flt3ITD/+and Flt3D835Y/+ progenitors that may be responsible for the survival differences between 
the two models, and ultimately patients with the two mutations. Expression patterns were more 




phenotype in D835Y mice, and known expression differences that remain similar to wild type as 
previously described. For the first time, we identified reciprocally expressed genes between the 
two mutant genotypes that may account for phenotypes diverging phenotypes observed in mice. 
Further investigation is necessary to define extensive pathway maps to indicate how these 
reciprocally expressed genes may fit into targetable pathways. 
  
2.5 Materials and methods 
2.5.1 RNA extraction and expression array 
Whole mouse bone marrow was extracted from Flt3ITD/+, Flt3D835Y/+, and wild type mice 
(4 mice per genotype) at 12-16 weeks of age, prior to overt disease onset.  LSK cells (Lin-c-
Kit+Sca-1+) were sorted using the FACS Aria (BD Biosciences). RNA was extracted from LSK 
cells using the RNeasy Micro Kit (Qiagen), and quality and concentration were subsequently 
assessed using the Bioanalyzer (Agilent).  Samples were then hybridized to the MouseWG-6 
v2.0 Microarray (Illumina) in the JHMI Deep Sequencing and Microarray Core. 
2.5.2 Analysis of expression array data 
Analysis of raw data. Text files containing the raw data were processed and analyzed 
using the Limma package in R.  All code for the these analyses can be found in Appendix 1.  The 
heatmap in figure 2-1B represents the 185 genes that are differentially expressed among wild 
type, Flt3ITD/+, and Flt3D835Y/+  LSK cells. These genes were identified by establishing a fold 
change cut off of 2, adjusted p value of 0.05. P values were adjusted using the Benjamani 
Hochberg method. The differentially expressed genes are represented in the Venn diagram in 
figure 2-1C. The 22 differentially expressed genes that are common to both mutant genotypes are 




2.5.3 Validation of candidate genes 
Target validation of reciprocally expressed genes. (Figures 2-2 and 2-3) RNA was 
extracted from Lineage negative bone marrow from wild type, ITD, and D835Y mice using 
TRIzol (Invitrogen), and reverse transcribed using the iScript cDNA Synthesis Kit (Bio-Rad).  
Quantitative RT-PCR was performed using the iCycler iQ multicolor real-time PCR system 
(Bio-Rad), and transcript levels were normalized to Rps16.  Primers used are in (Table 2-1). Fold 
changes were caldulated using the delta-delta Ct method. 
2.5.4 Analysis of Reactive Oxygen Species 
Lineage negative bone marrow cells were collected at the specified time points, and 
seeded at 100,000 cells per well in 12 well dishes in RPMI 1640. Cells were incubated with 
CellROX deep Red reagant (ThermoFisher) at a final concentration of 5uM for 30 minutes at 
37oC. Cells were washed, and subjected to subjected to flow cytometry. The MFI graphed in 
figure 2-3E is calculated by subtracting MFI(CellROX)-MFI(unstained)   
2.5.5  BaF3 cell culture 













2.6 Tables: Chapter 2 


















Socs2 F GAG CTC AGT CAA ACA GCA TGG
Socs2 R CGG TCC AGC TGA CGT CTT A
Dntt F GAA GCC ACA GAG GAT GAA GAG
Dntt R GAC TCT AAG ATG TCG CAG TAC AA
Il7R F AGT TGG AAG TGG ATG GAA GTC
Il7R R CAG CTT GTT AAG AGT TAG GCA TTT
Cox6a2 F GAC CTT TGT GCT GGC TCT T
Cox6a2 R CGA AGG GCT TGG TTC GG
Sgk1 F CCA AGT CCC TCT CAA CAA ATC A
Sgk1 R CCT AGC CAG AAG AAC CTT TCC
Rps16 F CCA ATT TGA ATG TGC CTG GA




2.7 Figures: Chapter 2 
Figure 2-1. Hierarchical clustering and heatmap of differentially expressed genes 
     
 
A) Hierarchical clustering dendrogram depicting relatedness of Flt3ITD/+, Flt3D835Y/+, and wild 
type LSK cells based on expression patterns. Each arm represents a sample used in the 
microarray.  One of the Flt3ITD/+ samples had to be excluded due to poor performance. B) 
Heatmap of the differentially upregulated (red) and downregulated (blue) genes meeting cut off 
criteria. C) Venn diagram with numbers of differentially expressed genes per genotype. D) 

















Lineage negative bone marrow from 8-20 week old mice of each genotype was subjected to 
qPCR.  Expected fold changes from the microarray are in boxes beneath each gene.  
Reciprocally expressed genes Dntt and Kdm7a are validated, as well as Gata2, which is 















(A) qPCR amplification of Cox6a2 from lineage negative bone marrow from mice of each 
genotype at varying ages. Boxes underneath the 20 week time point indicate the expected 
results from the microarray, as this later time point is most representative of those values.  
(B) Western blot using lysates from BaF3 cells shows increased Cox6a2 expression in 
D835Y cells, however ITD expressing cells don’t exhibit a decrease in protein levels as 
expected (C) Western blots from lineage negative cells of mice 6 weeks of age D835Y 
levels of Cox6a2 were increased compoared to the ITD, but we lacked a WT control. (D) 
Representative flow plots from lineage negative cells at 20 weeks of age assayed for 
ROS levels. (E) Mean fluorescence intensity (MFI) plotted for the same experiments for 













3. CHAPTER 3. Dnmt3a DELETION COOPERATES WITH THE Flt3-ITD MUTATION TO 
DRIVE LEUKEMOGENESIS IN A MURINE MODEL 
  
3.1 Introduction 
Large scale genomic studies have revealed the complex and heterogeneous genomic 
underpinnings of Acute Myeloid Leukemia (AML), identifying FLT3 as the most frequently 
mutated gene in the disease (Cancer Genome Atlas Research Network 2013; Welch,J.S. 2012;  
Patel,J.P. 2012), occurring in ~30% of AML patients. Internal tandem duplication (ITD) of the 
juxtamembrane domain is the most common of these mutations, and predicts poor clinical 
outcomes (Patel,J.P. 2012).  Previous studies in knock-in mice illustrate that Flt3ITD/+ alone 
generates myeloproliferative disease (MPN) and is insufficient to drive leukemogenesis, 
suggesting additional mutations are necessary for full transformation (Li,L. 2008; Lee,B.H. 
2007).  Global genomic sequencing studies have identified a substantial subset of patients in 
which FLT3/ITD and DNMT3A mutations are concomitantly present (Patel,J.P. 2012; Cancer 
Genome Atlas Research Network 2013). Moreover, the co-occurrence of these mutations is 
significantly associated with adverse clinical outcomes (Patel,J.P. 2012).  Typically in AML 
patients, sequencing studies have demonstrated 8-13 mutations but it is unclear how many of 
these mutations are drivers vs. passengers, leaving in doubt the number of mutations required for 
full transformation of primary cells (Vogelstein,B. 2013). Based on these observations, 
investigating the potential cooperativity of these mutations in a murine model serves to answer 
important questions regarding the underlying biology of the disease, while serving as a powerful 




 DNMT3A mutations are among the most common alterations in AML, just behind 
FLT3/ITD (Cancer Genome Atlas Research Network 2013; Welch,J.S. 2012; Ley,T.J. 2010).  
While AML-associated mutations have been identified throughout the body of the gene, the 
overwhelming majority are heterozygous missense mutations within the catalytic domain, often 
affecting Arginine 882 (Yang,L. 2015).  In vitro studies suggest the R882H mutation leads to 
reduced methyltransferase activity, and acts in a dominant negative manner by impairing 
tetramer formation (Russler-Germain,D.A. 2014; Kim,S.J. 2013; Holz-Schietinger,C. 2012).    
 In accordance with mounting evidence that DNMT3A mutations result in a loss of 
function, conditional knock-out mice have been used extensively to evaluate the effects of 
Dnmt3a loss on stem cell function and leukemia development (Mayle,A. 2014; Challen,G.A. 
2011). These mice harbor floxed Dnmt3a alleles (Dnmt3af/f), and a hematopoietic specific Cre 
transgene (Mx1-Cre+), which is induced upon injection with polyinosinic-polycytidylic acid 
(pIpC) (Kaneda,M. 2004). Recent work demonstrated that upon serial transplantation, Dnmt3a 
ablation in hemaotpoietic stem cells (HSC) promotes self-renewal and expansion of the LT-HSC 
pool, with progressive differentiation and methylation defects of downstream progeny 
(Challen,G.A. 2011; Jeong,M. 2014). As DNMT3A mutations are thought to represent one of the 
earliest founding events in AML (Xie,M. 2014; Shlush,L.I. 2014), these functional studies may 
explain how mutant DNMT3A initiates the disease, through expanding the primitive cell pool, 
thereby increasing the probability of acquiring additional deleterious mutations.  Conversely, 
Flt3/ITD disrupts LT-HSC quiescence, resulting in depletion of this compartment (Chu,S.H. 
2012). Given the co-occurrence of FLT3/ITD and DNMT3A mutations in AML patients, we 
hypothesized that Dnmt3a deletion may cooperate with Flt3/ITD to induce leukemia, potentially 




 Since DNMT3A mutations seem to represent an initiating event, breeding Dnmt3af/f  mice 
to our Flt3ITD/+   knock-in mice presents a significant challenge, as mutant Flt3 is expressed at 
the earliest stages of hematopoeisis, preceding Dnmt3a deletion. To partially circumvent this 
issue, we used a substrain of our Flt3ITD/+ knock-in mice which retains a floxed Neomycin (Neo) 
selection cassette from the initial targeting (Flt3ITDneo/+; referred to hereafter as Flt3ITD/+ for 
simplicity’s sake). The presence of the cassette greatly reduces expression of the mutant allele 
(Li,L. 2008). Flt3ITD/+ expression is fully restored upon excision of the cassette following Cre 
induction, effectively “knocking in” the Flt3/ITD mutation and knocking out Dnmt3a 
simultaneously (Figure 3-1A). This novel approach allowed us to perform long term survival 
studies and disease characterization in a biologically relevant context. 
 
3.2 Results 
3.2.1 Dnmt3a deletion reduces survival of Flt3ITD/+ knock-in mice in a dose dependent 
manner and drives leukemogenesis  
 In accordance with mounting evidence that DNMT3A mutations result in a loss of 
function (Russler-Germain,D.A. 2014), we used a mouse model harboring floxed Dnmt3a alleles 
(Dnmt3af/f) (Kaneda,M. 2004), and a lymphocyte specific Cre transgene (Mx1-Cre), which is 
activated upon injection with polyinosinic-polycytidylic acid (pIpC). These mice were bred to a 
substrain of our Flt3ITD/+ knock-in mice, which retains a floxed PGK-Neo selection cassette from 
the initial targeting (Figure 3-1A).  The presence of the cassette reduces transcription of the 
mutant allele, and full expression is restored upon Cre excision (Li,L. 2008).  Since DNMT3A 
mutations are thought to represent one of the earliest events in leukemia development (Xie,M. 
2014; Shlush,L.I. 2014; Welch,J.S. 2012), this approach provides the unique advantage of 




Flt3ITD mutation, and knocking out Dnmt3a simultaneously upon pIpC injection. Mx1-Cre 
expressing mice harboring Flt3ITD/+ and homozygous floxed Dnmt3a alleles (Flt3ITD/+;Dnmt3af/f), 
heterozygous (Flt3ITD/+;Dnmt3af/+), or wild type alleles (Flt3ITD/+), as well as litter mate controls 
(Flt3+/+;Dnmt3af/f  or Flt3ITD/+;Dnmt3af/+ lacking the Mx1-Cre transgene) were injected with 
pIpC intraperitoneally at 8 weeks of age and monitored for disease development. Peripheral 
blood was collected every 1-2 months after injection to monitor changes in the differential white 
blood count, and to collect genomic DNA to confirm effective loxP recombination (table 3-1). 
 Interestingly, deletion of Dnmt3a significantly reduced median survival of Flt3ITD/+ mice 
in a dose-dependent manner, with median survival of 162 days and 256 days for 
Flt3ITD/+;Dnmt3af/f and Flt3ITD/+;Dnmt3af/+, respectively (Figure 3-1B). Both genotypes confer a 
significantly shorter survival time compared to Flt3ITD/+ mice alone, which have a median 
survival of 412 days, consistent with our previous findings (Greenblatt,S. 2012; Bailey,E. 2013; 
Li,L. 2008).  Dnmt3a dosage was also associated with a number of other parameters, including 
splenomegaly (Figure 3-1C) and leukocytosis (Figure 3-1D). While the trending increase in 
spleen weight and WBC is evident, only Flt3ITD/+ mice with complete loss of Dnmt3a 
(Flt3ITD/+;Dnmt3af/f ) displayed increases reaching statistical significance compared to Flt3ITD/+ 
alone.  
Dnmt3a deletion cooperates with Flt3ITD/+ to induce a broad spectrum of neoplasms 
As expected from previous work, mice with Flt3ITD/+ alone developed MPN, while loss 
of one or both Dnmt3a alleles cooperates with the Flt3ITD mutation to elicit leukemia 
development of varying lineages including AML, MPN, and T lymphoblastic 




mice with myeloid diseases revealed predominance of blasts and immature myeloid cells in 
AML samples (Figure 3-2B). While T-LLs displayed variable immunophenotypes, including 
double or single positive for CD4 or CD8 (data not shown), the immunophenotype among 
myeloid mice was fairly uniform, displaying an increase in blasts that are FcrG+, CD34+, 
Mac1+/lo, consistent with a Myelomonocytic leukemia (Figure 3-2C).  
In FLT3/ITD+ AML, loss of heterozygosity of the wild type allele is sometimes 
observed, and is associated with poorer survival (Meshinchi,S. 2006; Whitman,S.P. 2001; 
Thiede,C. 2002).  To investigate whether or not this phenomenon also occurred in our model, 
genomic DNA was extracted from bone marrow and matched tail tissue from leukemic mice, and 
PCR amplification was performed using primers flanking the ITD mutation (Figure 3-3A).  Loss 
of the wild type allele was observed in 36% (5/14) of mice developing AML (both 
Flt3ITD/+;Dnmt3af/f and Flt3ITD/+;Dnmt3af/+), while no evidence of LOH was observed in any of 
the 13 mice developing lymphoid neoplasms (Figure 3-3B).  These findings are consistent with 
previous studies in Flt3ITD/+ knock-in mice, where loss of the wild type allele is restricted to 
AML, and absent in T-LL (Rau,R. 2014; Greenblatt,S. 2012), indicating a selective advantage 
for these events specifically in the myeloid lineage. 
3.2.2 T-LL samples exhibit enhanced transplantability compared with other neoplasms 
To investigate transplantability of primary neoplasms developing in our mice, cells from 
each leukemic donor were transplanted into three sublethally irradiated recipients and monitored 
for survival (Figure 3-3C). Engraftment and survival were variable based on disease subtype, as 
all 4 of the AML samples from Flt3ITD/+;Dnmt3af/f donors engrafted, with a median survival of 
174 days, while only 2 of 4 Flt3ITD/+;Dnmt3af/+ AML samples engrafted, displaying slightly 




from Flt3ITD/+ mice failed to engraft, consistent with previous findings (Li,L. 2008). In stark 
contrast, T-LL samples from both Flt3ITD/+;Dnmt3af/f and Flt3ITD/+;Dnmt3af/+genotypes were 
much more aggressive, killing recipients within one month. 
3.2.3 Lymphocytic neoplasms exhibit Notch1 mutations and repressed Flt3 expression  
Since LOH of the ITD allele was found to be a disease specific finding, associated with  
AML samples specifically, we were interested in identifying lymphoid specific mutations as 
well. Activating mutations in NOTCH1 are the most frequent mutation in T-ALL (Liu,H. 2011; 
Liu,H. 2010). To detect Notch1 mutations in our samples, we performed RT-PCR, and amplified 
hot spots for common mutation sites within the heterodimerization and PEST domains, sending 
them for sequencing. In all samples where adequate material was available, we identified 
mutations which are predicted to be activating (table 3-2). These mutations were lymphoid 
disease specific, as expected. 
Previous sequencing endeavors have identified DNMT3A and FLT3 as frequently mutated 
genes in AML, both individually and concurrently, and at lower frequencies in T-ALL 
(Neumann,M. 2013; Grossmann,V. 2013; Neumann,M. 2012). While lymphocytic leukemias 
haven’t previously been observed in our Flt3ITD/+ knock-in model, previous work has 
demonstrated that ~15% of Dnmt3af/f mice develop T-ALL (Mayle,A. 2014), with median 
survival of 246 days, compared with 162 days in our Flt3ITD/+;Dnmt3af/f  mice. Taken together, 
these findings suggest that perhaps the Flt3/ITD mutation is dispensable for maintenance of 
lymphoid malignancies in Flt3ITD/+;Dnmt3af/f  mice, but may play an important role in expanding 





To examine Flt3 expression, we performed qPCR on whole bone marrow from wild type 
and Flt3ITD/+;Dnmt3af/f  mice with varying diagnoses.  Flt3 expression was elevated in myeloid 
neoplastic samples, especially those exhibiting LOH, with expression levels at about 11 fold 
higher than wild type bone marrow samples (Figure 3-3D). Interestingly, T-LL samples 
expressed virtually no Flt3, supporting the hypothesis that once full transformation occurs in 
these cells, Flt3 is turned off, as in normal lymphoid development (De Obaldia,M.E. 2013). 
3.2.4  Myeloid progenitors are expanded in double mutant mice at an early time point, 
underlying observed relative monocytosis and disease variability 
Recent work has demonstrated that Dnmt3a deletion in hematopoietic stem cells (HSC) 
promotes self-renewal and expansion of the LT-HSC pool (Challen,G.A. 2011), resulting in 
leukemia with incomplete penetrance and prolonged time to disease development (Mayle,A. 
2014).  Conversely, Flt3ITD/+ disrupts LT-HSC quiescence, resulting in depletion of this 
compartment, and failure to develop full blown leukemia in the absence of cooperating mutations 
(Chu,S.H. 2012). We hypothesized that enhanced self-renewal and expansion in the LT-HSC 
compartment conferred by Dnmt3a deletion might “rescue” the LT-HSC depletion seen in 
Flt3ITD/+ mice, thereby increasing this primitive pool and the opportunity for additional mutations 
necessary to drive either myeloid or T cell leukemia to develop.  To investigate the frequencies 
of progenitor populations well prior to disease onset, mice were sacrificed at 8 weeks post pIpC 
injection and the stem cell compartment was examined by flow cytometry. 
While overt leukemia was absent at this early time point, pathological changes were 
evident in the bone marrow and peripheral blood.  None of the genotypes exhibited leukocytosis 
(Figure 3-4A), but a relative monocytosis was seen, as expected, in Flt3ITD/+ mice, and was 




percentage of monocytes, and concomitant decrease in percent lymphocytes (Figure 3-4B).  
While Dnmt3a ablation alone had no effect on spleen size at 8 weeks, splenomegaly was noted in 
Flt3ITD/+ mice, which was again more pronounced in double mutant mice (Figure 3-4C). Flow 
cytometric analysis of whole bone marrow displayed varying anomalies, including aberrant 
CD34 expression and expansion within the myeloid lineage (Figure 3-4D).   This 
immunophenotypic variability at an early time point likely underlies the ultimate variability in 
neoplasms developing in moribund mice. Interestingly, while percentage shifts favoring myeloid 
cell types in the peripheral blood were similar between Flt3ITD/+;Dnmt3af/+ and 
Flt3ITD/+;Dnmt3af/f mice, appreciable shifts in myeloid progenitor populations were only present 
in the Flt3ITD/+;Dnmt3af/f  bone marrow samples, where obvious increases in common myeloid 
(CMP) and granulocyte-macrophage (GMP) progenitors were observed with a decrease in 
megakaryocyte-erythrocyte progenitors (MEP) (Figure 3-4E). 
3.2.5 Loss of both copies of Dnmt3a is necessary to elicit LT-HSC expansion 
Upon examining the stem cell compartment, we confirmed the previously described 
expansion in Dnmt3a knock-out mice and depletion in Flt3ITD/+ mice. The data suggest that loss 
of one Dnmt3a allele is sufficient to restore the LT-HSC (Lin− c-kit+ Sca-1+ Flt3−CD34−) pool of 
Flt3ITD/+ mice to wild type proportions, while loss of both Dnmt3a alleles together with Flt3/ITD 
expression results in a dramatic expansion, beyond that of Dnmt3af/f  alone (Figure 3-5A). Given 
the previous findings that Dnmt3a deletion expands the LT-HSC compartment through enhanced 
quiescence, the observed minor decrease in the immediate downstream ST-HSC (Lin− c-kit+ Sca-
1+ Flt3−CD34+) (Figure 3-5B) and MPP (Lin− c-kit+ Sca-1+ Flt3+CD34+) (Figure 3-5C) 
populations in Dnmt3af/f  mice is not surprising. Likewise, as aberrant exit from quiescence 




differentiate, as evidenced by an observed increase in the ST-HSC (Figure 3-5B) and MPP 
(Figure 3-5C) pools.  Similar to the LT-HSCs, haploinsufficiency of Dnmt3a in 
Flt3ITD/+;Dnmt3af/+ mice was sufficient to bring the fraction of ST-HSCs back towards the wild-
type levels. In contrast, loss of both Dnmt3a alleles in Flt3ITD/+;Dnmt3af/f mice resulted in a 
dramatic increase in the ST-HSC compartment (Figure 3-5B). Dnmt3a deletion in the Flt3ITD/+ 
context conferred an increase in the MPP population in a dose dependent manner (Figure 3-5C). 
3.2.6 Dnmt3a ablation enhances colony formation of Flt3ITD/+ bone marrow in serial 
replating experiments 
After determining that Dnmt3a loss and the Flt3/ITD mutation do indeed cooperate to 
greatly expand the LT-HSC pool, we sought to investigate the mechanism underlying this 
observation.  To assess self-renewal, lineage negative bone marrow cells were plated on 
methylcellulose, and serially re-plated twice more. The number of colonies was recorded before 
each re-plating.  Since the methylcellulose used in these experiments contains cytokines 
directing myeloid differentiation, persistence of colony forming cells in the third plating suggests 
a block in differentiation and enhanced self-renewal.  As expected, wild type bone marrow 
displays a significant decrease in colony formation at the secondary plating and an absence of 
colonies at the tertiary re-plating.  In agreement with previous observations, Dnmt3af/f cells 
continued to re-plate through the tertiary plating, exhibiting enhanced self-renewal. Only one 
tertiary re-plating colony was observed of all plates analyzed from Flt3ITD/+ mice, congruent with 
disrupted quiescence (Figure 3-5D). However, when Dnmt3a loss is added to the Flt3ITD/+ 
background, partial restoration of the enhanced self-renewal phenotype is observed.  These 
experiments suggest that the expansion in the LT-HSC pool of Flt3ITD/+;Dnmt3af/f  mice is 





Throughout the last decade, thorough analysis of the leukemia genome has generated an 
extensive compendium of AML-associated mutations (Welch,J.S. 2012; Cancer Genome Atlas 
Research Network 2013).  These data have formed the basis for subsequent functional studies in 
mice, using knock in, knock out, or transgenic strains.  Mutation of the orthologous mouse gene 
represents the most biologically relevant experimental approach, yet many of the most common 
driver mutations do not, in isolation, lead to fully penetrant, rapidly fatal leukemias ( Lee,B.H. 
2007; Li,L. 2008; Bailey,E. 2013; Li,Z. 2011; Moran-Crusio,K. 2011; Moran-Crusio,K. 2011; 
Chan,G. 2009). These results are not surprising, as elegant studies dissecting the clonal evolution 
of leukemia indicate several mutations occur in concert, often chronologically, and are likely 
necessary for transformation.   
Integrative genomic profiling has identified a significant proportion of AML patients 
with concomitant FLT3-ITD and DNMT3A mutations. Concurrently, these mutations stratify 
patients into a poorer prognostic category, predicting inferior clinical outcomes and overall 
survival (Patel,J.P. 2012).  While Flt3/ITD knock-in alone fails to fully transform and 
recapitulate human leukemia, ablation of Dnmt3a alone is sufficient to predispose HSCs to 
malignant transformation, resulting in a spectrum of neoplasms with a prolonged time to disease 
development (Mayle,A. 2014).  We hypothesized that breeding Flt3ITD/+ mice and the conditional 
Dnmt3a knock-out would result in shortened survival compared to either mutation alone, 
cooperating to drive AML development in a greater proportion of mice than Dnmt3af/f alone.  
The data reported here confirm that indeed, Flt3ITD/+ and bone marrow specific Dnmt3a 
deletion cooperate to result in shortened survival due to fatal hematopoietic neoplasms, including 




spectrum of neoplasms developing in Flt3ITD/+ mice. The observation that loss of a single allele is 
sufficient to shorten survival and elicit leukemia development highlights the importance of 
Dnmt3a stoichiometry in maintaining appropriate hematopoietic stem cell function.  This finding 
is especially relevant in light of a recent meta-analysis of the TCGA cohort, which revealed a 
significant focal loss of CpG methylation throughout the genomes of AML patients harboring 
DNMT3A mutations (Russler-Germain,D.A. 2014). Mean beta values were also further reduced 
in DNMT3AR882 compared to DNMT3Anon-R882 samples, supporting in vitro evidence that R882 
mutations impair methyltransferase activity more severely than mutations at other residues.  
Future assessment and comparison of these Flt3ITD/+;Dnmt3af/+ and Flt3ITD/+;Dnmt3af/f  mice 
with human FLT3ITD;DNMT3Anon-R882   and FLT3ITD;DNMT3AR882 AML methylomes may 
reveal differentially methylated loci that are dosage, rather than sequence context dependent. 
Unlike AML, which is characterized by heterozygous DNMT3A mutations primarily in 
the methyltransferase domain, the gene is frequently biallelically inactivated in T-ALL, with 
mutations occurring throughout the body of the gene (Yang,L. 2015).  Homozygous ablation of 
Dnmt3a in our mice may mimic biallelic inactivation seen in patients, accounting for the 
incidence of the disease in these mice.  While Flt3 is virtually unexpressed in T-LL derived from 
our double mutant mice, this does not preclude the possibility that Flt3/ITD is important for 
expansion of a lymphocytic progenitor, with cooperating somatic mutations and epigenetic 
changes favoring transformation within a later compartment, where FLT3 activity is dispensible 
(De Obaldia,M.E. 2013).  The identification of FLT3 mutations in a subset of T-ALL patients 





 Variance in phenotype and delay in disease development may indicate that cells in the 
context of both mutations are still predisposed to transformation, but require additional 
mutations.  Although leukemic mice meet the diagnostic criteria consistent with AML, 
including >20% blasts, inconsistent engraftment makes it difficult to perform transplantation 
experiments and in vivo drug treatments.  A recent study in AML1-ETO driven murine leukemia 
illustrates the utility and power of cross referencing genomic data from murine studies with the 
enormous repository of publicly available data from human leukemia samples sharing the same 
genetic underpinnings (Hatlen,M.A. 2015).  Using a similar approach in our model, we hope to 
identify cooperative orthologous genomic events which we can introduce into Flt3ITD/+;Dnmt3af/f  
bone marrow, thereby creating an increasingly relevant model of the disease, increasing 
aggressiveness and facilitating in vivo TKI and epigenetic combination therapy testing. 
 This model presents a platform to answer important questions regarding Dnmt3a dosage 
in the context of Flt3/ITD.  Prior to leukemia formation, the incremental expansion of the LT-
HSC pool indicates that differentially methylated loci important in maintaining quiescence can 
be determined.  It will be important to assay whether or not dosage simply influences 
methylation density within the same discrete genomic regions, or perhaps stoichiometry directs 
repressive complexes to novel loci. 
3.4 Conclusions 
The data presented in this report assert, for the first time, that conditional deletion of 
Dnmt3a and simultaneous “knock in” of Flt3ITD/+, cooperate to drive leukemia development at a 
faster rate than Dnmt3a loss alone. Loss of heterozygosity of the Flt3 allele in our double mutant 
AMLs further substantiates our model as a powerful tool to study human leukemogenesis, as 




the stem cell compartment at an early time point, double mutant AML blasts, and comparisons 
with human FLT3-ITD/DNMT3A mutant AML will reveal common core pathways and 
therapeutic targets, providing a vital resource to investigate clinically relevant therapies. 
3.5 Materials and methods 
3.5.1 Mice. 
Mice harboring floxed Dnmt3a alleles (Dnmt3af/f ) and an inducible hematopoietic specific Cre 
transgene (Mx1-Cre) (Kaneda,M. 2004) were bred to a substrain of our Flt3ITD/+ knock-in mice 
(Li,L. 2008) which retain a floxed PGK-Neo cassette from the initial targeting (Figure 3-1A). 
Dnmt3a knock-out, and excision of the PGK-Neo cassette within the Flt3ITD/+ allele, were 
achieved by two intraperitoneal injection of pIpC (250ug/mouse in PBS; Invivogen) every other 
day.  Genomic DNA was prepared from peripheral blood eight weeks after pIpC injection to 
confirm loxP recombination at both alleles (Table 3-1) Primers used for genotyping and 
confirmation of loxP recombination (Flox F & Flox R) can be found in Table 3-1. Diagnoses and 
classification of hematopoietic neoplasms were made based on the previously established 
Bethesda proposals ( Kogan,S.C. 2002; 27 Morse,H.C.,3rd 2002).  All animal experiments were 
performed according to protocols approved by the Animal Care and Use Committee of Johns 
Hopkins University in accordance with guidelines set forth by the National Institutes of Health. 
3.5.2 Disease characterization. 
Complete peripheral blood cell count and cytology. Mice were monitored and sacrificed when 
they exhibited signs of disease development (lethargy, ruffled coat, abnormal complete blood 
count (CBC) differential). Peripheral blood was collected from the facial vein and subjected to 
complete blood cell counting, and a WBC differential was performed using the Hemavet950 




using a modified Wright-Giemsa protocol (Sigma-Aldrich), and representative images were 
acquired using a Zeiss Axioskop upright microscope (Carl Zeiss). 
Flow cytometry. Diagnostic flow cytometric analysis was performed as previously described 
{{6 Li,L. 2008;}}.  Data were analyzed using FlowJo Version 9.3.3 software (TreeStar).  
Transplantation.  1x10^6 whole bone marrow cells from leukemic mice were transplanted into 
sub-lethally irradiated C57Bl/6-CD45.1 recipients (7.5 cGy) by tail vein injection.  Blood was 
collected from the facial vein every 3-4 weeks for CBCs and flow cytometric analysis of 
engraftment.  Additionally, recipients were monitored for visible signs of disease development. 
3.5.3 RT-PCR and mutation analysis 
Loss of Heterozygosity (LOH) analysis of Flt3 allele. Genomic DNA was extracted from tail 
tissue, whole bone marrow, thymus, or lymph node where appropriate, using the Wizard 
Genomic DNA Purification Kit (Promega).  PCR amplification was performed using 50ug of 
genomic DNA with Flt3 genotyping primers flanking the ITD mutation Table 3-1.  
RT-PCR and Flt3 expression analysis. RNA was extracted from whole bone marrow, thymus, 
or lymphnode where appropriate using TRIzol (Invitrogen), and reverse transcribed using the 
iScript cDNA Synthesis Kit (Bio-Rad).  Quantitative RT-PCR was performed using the iCycler 
iQ multicolor real-time PCR system (Bio-Rad), and transcript levels were normalized to Rps16.  
Primers spanning exons 16 and 17 were used to detect Flt3 expression Table 3-1. 
Notch1 mutation analysis. RNA extraction and RT-PCR were performed as above.  To detect 
Notch1 mutations, primers specific for the heterodimerization and PEST domains were used to 




(Invitrogen) and 10 colonies per product were picked and Sanger sequenced. Sequences for all 
primers can be found in the Table 3-1. 
3.5.4 Stem cell quantification and analysis. 
Quantification of progenitors. Eight weeks post pIpC injection, whole bone marrow was 
isolated, and stem cell and progenitor populations were quantified as previously described {{4 
Chu,S.H. 2012;}}.  Phenotypic definitions of these compartments are as follows: LSK: Lin−Sca-
1hic-KIThi; LT-HSC: Lin−Sca-1hic-KIThiCD34−CD135−; ST-HSC: Lin−Sca-1hic-
KIThiCD34+CD135−; MPP: Lin−Sca-1hic-KIThiCD34+CD135+; CMP: Lin−Sca-1−c-
KIThiCD34+CD16mid; GMP: Lin−Sca-1−c-KIThiCD34+CD16hi; MEP: Lin−Sca-1−c-
KIThiCD34−CD16−. 
Colony formation assays. Bone marrow was isolated from mice 8 weeks post pIpC injection, 
and subjected to lineage depletion using the MACS cell separation system (Miltenyi Biotec).  
10,000 lineage negative bone marrow cells were plated on Methocult M3434 (Stemcell 
Technologies), and analyzed at day 9-11.  Colonies were disaggregated, and 200 cells were re-
plated and scored for subsequent secondary and tertiary colony formation.  Three mice were 
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Table 3-2. Notch1 mutations in lymphoid neoplasms. 
 
Genotype Immunophenotype        Domain Mutation 
Flt3ITD/+;Dnmt3af/+   CD4+ PEST c.7539delG (p.2439fs*2451) 
Flt3ITD/+;Dnmt3af/+   DP* HD c.T5040G, 5040insGAG  
(p.F1592L, 1592insE) 
Flt3ITD/+;Dnmt3af/f   DP PEST c.7354insAGGGGGG 
(p.2356fs*2494) 
Flt3ITD/+;Dnmt3af/f   DP PEST c.7154del(22)  (p.2285fs*2301) 
Flt3ITD/+;Dnmt3af/f   CD4+ HD c.G5179A (p.A1639T) 
Dnmt3af/f   DP PEST c.7539delG (p.2439fs*2451) 
 
 







3.7 Figures: Chapter 3 
Figure 3-1. Dnmt3a deletion cooperates with Flt3ITD/+ to shorten survival in a dose dependent 
manner.   
 
(A) Strategy for temporally controlling Flt3/ITD expression using a substrain of our Flt3ITD/+ 
knock-in mice.  The substrain (Flt3ITDneo/+) retains the PGK-Neo cassette inserted at the mutant 
allele (referred to hereafter as Flt3ITD/+). The presence of the cassette reduces expression of the 
mutant allele (dashed green arrow), and Flt3ITD/+ expression is fully restored upon excision of the 
cassette following cre induction (solid green arrow). (B) Kaplan-Meier Survival Curve. Median 
survival is 162 days for Flt3ITD/+ ;Dnmt3af/f (n=24), 260 days for Flt3ITD/+ ;Dnmt3af/+ (n=20), and 
412 days for Flt3ITD/+  alone (n=12 ). (C) Spleen weights, and (D) White blood cell counts 




ITD alone (Flt3ITD/+); Flt3ITD/+;Dnmt3af/+ (Flt3ITD/+ ;f/+); Flt3ITD/+;Dnmt3af/f(Flt3ITD/+ ;f/f). (*, p < 


























Figure 3-2. Dnmt3a deletion cooperates with Flt3ITD/+ to induce a broad spectrum of 
neoplasms.  
 
A)  Disease distribution of Flt3
ITD/+ 
mice lacking both (left) or a single (right) Dnmt3a allele. (B) 
Hematoxylin and Eosin stained bone marrow cytospins from a representative wild type mouse 
(WT, left column), a mouse with a Myeloproliferative Neoplasm (MPN, center column), and a 
mouse with Acute Myeloid Leukemia (AML, right column). (C)  Flow cytometric analysis of 




leukemic mouse on the right displays an abnormal Mac1+Gr1lo/- population.  (ii) The wild-type 
mouse (left), displays the normal CD34 positivity, while MPNs exhibit increased immature 
CD34+,  cells which are Mac-1
lo/-
 , but fail to reach and exceed the 20% requirement for an AML 
diagnosis.  This same population exceeds 20% in the representative AML plot on the right. That 






Figure 3-3. Loss of Heterozygosity (LOH) and Flt3 expression are present in a disease specific 
manner. 
 




surrounding the ITD mutation were used to amplify genomic DNA prepared from bone marrow 
and matched tail tissue from leukemic mice. (B). Loss of Heterozygosity (LOH) of the wild type 
Flt3 allele occurs exclusively in mice developing AML, in both Flt3ITD/+;Dnmt3af/f and 
Flt3ITD/+;Dnmt3af/+ genotypes. Summary of samples exhibiting loss of the wild type Flt3 allele 
(C) Survival summary of transplantation experiments. Diseases of donors and median survival of 
all engrafted recipients are noted. (D) T-ALLs are driven by Flt3/ITD independent factors. qPCR 
of leukemic tissue displays silencing of Flt3 in lymphocytic leukemia samples. RNA was 
extracted from whole bone marrow of Wildtype (WT), or Flt3ITD/+;Dnmt3af/f  mice developing 






Figure 3-4. Early signs of disease development and myeloid expansion are present at 8 weeks 
post pIpC injection. 
 
 
(A)White Blood Cell counts (WBC) remain wtihin the normal range for all genotypes. (B) 
Relative monocytosis is observed upon CBC, despite normal WBC.  WT and Dnmt3af/f exhibit 
normal leukocyte ratios, while Flt3ITD/+ mice display an increase in percentage of neutrophils and 
concomitant decrease in percentage of lymphocytes. When these mice lose one or both Dnmt3a 
alleles, the phenotype is exaggerated with further decrease in relative lymphocytes and an 
increase in the percentage of monocytes.(C)Spleen weight is increased only in mice harboring a 
Flt3/ITD mutation. Splenomegaly is further enhanced with loss of one or both Dnmt3a alleles. 
(D) Flow cytometric analysis of bone marrow at an early time point reveals dysplastic changes . 




are present. Wildtype (WT); Flt3-ITD alone (Flt3ITD/+ ); Flt3ITD/+;Dnmt3af/+ (Flt3ITD/+;f/+); 































(A) LT-HSC, (B) ST-HSC, and (C) MPP populations were quantified by flow cytometric 
analysis of whole bone marrow of mice at 8 weeks post pIpC n=3 per genotype. (D) 
Serial replating of Lineage negative bone marrow at 8 weeks post pIpC from 3 mice per 




























4. CHAPTER 4. ADDITION OF MUTANT NPM1 INCREASES DISEASE 
AGGRESSIVENESS IN Flt3ITD/+;Dnmt3af/f  MICE 
 
4.1 Introduction 
Nucleophosmin family member 1 (NPM1) is a nucleolar protein which shuttles between 
the nucleus and cytoplasm to exert a number of critical cellular functions, including ribosomal 
biogenesis, controlling cell growth through transcriptional regulation, and maintaining genomic 
stability (Grisendi,S. 2006), and represents one of the frequently mutated genes in leukemia 
(Falini,B. 2009; Patel,J.P. 2012; Grisendi,S. 2006). Similar to the DNMT3A mutations that have 
been identified, NPM1 mutations are thought to result in a loss function in several leukemia 
subtypes. Reciprocal translocations have been identified in certain subsets of leukemia and 
lymphoma, resulting in haploinsufficiency, as only one wild type copy remains intact 
(Grisendi,S. 2006). As a transcriptional regulator, the decrease in functional NPM1 protein is 
thought to drive oncogenesis through failing to control expression of genes important in 
restricting cellular growth. 
In the setting of normal karyotype AML (NK-AML), NPM1 mutations are heterozygous.  
Referred to as NPMc+, these mutations disrupt the nucleolar localization signal in the 
cytoplasmic portion of the protein, and replace it with a novel nuclear export motif (66 Falini 
2006). Abnormal nuclear export leads to accumulation of the protein in the cytoplasm resulting 
in failed p53-dependent cell cycle arrest due to the inability of mutant NPM1 to interact with 
p19Arf  (Falini,B. 2009). Given the frequent co-occurrence of FLT3 and NPMc+ mutations 
(Patel,J.P. 2012), our collaborators recently bred our classical Flt3ITD/+ mice with a transgenic 




(Rau 2014). While a proportion of these mice do develop AML, the lag time is sufficiently long 
such that additional cooperating events may be necessary to accelerate disease development and 
result in a greater proportion of animals developing AML. 
A recent TCGA publication identified a unique patient population harboring mutations in 
DNMT3A, FLT3, and NPMc+ concurrently, exhibiting common clinical features (16 Cancer 
Genome Atlas Research Network 2013).  Breeding the hMRP8-NPMc+ onto the 
Flt3ITD/+;Dnmt3af/f  background presents the an opportunity to study the potential cooperativity of 
the three mutations in vivo. We hypothesized that these mutations would result in a shorter 
median survival compared to the 162 day survival observed in Flt3ITD/+;Dnmt3af/f mice in the 
previous chapter. The results presented in this chapter are extremely preliminary, and additional 
experiments are currently underway. 
 
4.2 Results 
4.2.1 Flt3ITD/+;Dnmt3af/f;NPMc+ mice exhibit shortened survival and AML 
Just as in the previous chapter, mice were injected with pIpC and followed for signs of 
disease development. Data for this chapter is admittedly sparse, but interestingly, 
Flt3ITD/+;Dnmt3af/f;NPMc+ mice was almost uniformly died at 152 days, which was also the 
median survival in this population (n=9) (Figure 4-1A). While this shortens survival by about ten 
days compared to Flt3ITD/+;Dnmt3af/f mice, the difference didn’t reach statistical significance. 
Additionally, while the sample size is too small to draw any conclusions about disease spectra, 
64% of mice develop AML, while 36% develop T-ALL (Figure 4-1B). Of note, unlike 
Flt3ITD/+;Dnmt3af/f which develop MPN in addition to the other full blown leukemias, addition of 





In this report, we have begun to analyze, for the first time, the contribution of 
three, commonly concurrently mutated genes. Thus far, we only have appreciable data for 
Flt3ITD/+;Dnmt3af/f;NPMc+ mice, and have determined so far that they almost uniformly 
die at 152 days, with the majority developing AML. As a corollary, the addition of 
mutant NPMc+ seems to drive these mice down a myeloid fate, with a more aggressive 
disease, increasing the number of blasts present in these mice (data not shown). It will be 
interesting to assess whether Dnmt3a dosage will affect survival and stem cell properties 
in the presence of mutated NPM1. Additionally, it is known the DNMT3A and NPM1 are 
concurrently mutated (with wild type FLT3). We have included this genotype as well 
(Dnmt3af/f;NPMc+) in our analysis, as no one has performed this experiment. These mice 
particularly provide an important resource to look at the contribution of mutant Flt3 to 
disease development, survival, and genomic changes on the molecular level. Additional 
studies are underway to provide insight into loss of just one Dnmt3a allele in the triple 
mutant mice,  
 
4.4 Conclusions 
To our knowledge, we are the only group investigating a model in which Flt3 
Dnmt3a, and Npm1 are all mutated, representing a potential new took to model a new 
subtype of patients that has recently been recognized in which all three genes are 
mutated. These studies are ongoing to increase the number mice in each genetic cohort, 





4.5 Material and methods 
4.5.1 Mice.  
Transgenic mice expressing Flag-tagged human NPMc+ mutant driven by human MRP8 
promoter (hMRP8-NPMc+) were generated as previously reported (Cheng,K. 2010). These mice 
were bred with the mice described in section 3.5.1, and pIpC injections were performed as 
described in this section as well. Genotyping primers and those to assess effective knock-out are 
described in Table 3-1. Additionally, to genotype for the NPMc+ transgene the following 
primers were used NPM874F-GGT TCT CTT CCC AAA GTG GAA GC, MRP8R- GAG GTA 
TTG ATG ACT TTA TTA TTC TGC AGG. Diagnoses and classification of hematopoietic 
neoplasms were made based on the previously established Bethesda proposals (Kogan,S.C. 2002; 
Morse,H.C.,3rd 2002).  All animal experiments were performed according to protocols approved 
by the Animal Care and Use Committee of Johns Hopkins University in accordance with 
guidelines set forth by the National Institutes of Health. 
 
4.5.2 Disease characterization.  
Complete peripheral blood cell count and cytology. Mice were monitored and sacrificed when 
they exhibited signs of disease development (lethargy, ruffled coat, abnormal complete blood 
count (CBC) differential). Peripheral blood was collected from the facial vein and subjected to 
complete blood cell counting, and a WBC differential was performed using the Hemavet950 
system (Drew Scientific). Bone marrow cytospins and peripheral blood smears were stained 
using a modified Wright-Giemsa protocol (Sigma-Aldrich), and representative images were 




Flow cytometry. Diagnostic flow cytometric analysis was performed as previously described 








4.6 Figures: Chapter 4 




(A) Kaplan-Meier Survival Curve. This curve is identical to the survival curve in figure 3-1B, 
with the addition of the red line, representing Flt3ITD/+;Dnmt3af/f;NPMc+ with a median survival 





5. CHAPTER 5. CONCLUDING REMARKS 
 
 
5.1 Knock-in of specific FLT3 mutations in mice facilitates study of signaling 
differences 
Chapter 2 recounts the underlying differences between AML patients bearing FLT3-ITD 
and FLT3-KD mutations. With significant prognostic differences in these populations, murine 
models bearing mutations in the respective endogenous murine loci present an opportunity to 
study the contributions of each of these mutations in a genetically pure setting. We previously 
saw that the Flt3-ITD knock-in mice solely develop MPN, and succumb to disease much more 
rapidly (350 days vs 600 days) than the Flt3-KD model, recapitulating the patient survival data. 
The fact that Flt3-KD mice develop lymphoid diseases, and others MPN, may point to key 
differences between the two mutations and the pathways they act upon. 
After performing an expression array, it was clear that expression signature of progenitor 
cells from the Flt3-KD mice were similar to the Flt3-ITD samples. These results are not 
surprising since the disease course for FLT3-ITD patients is far more aggressive. In analyzing 
the data and performing additional validation, I determined that Dntt (or Tdt), a protein essential 
to creating receptor diversity in the lymphocytes, was reciprocally expressed in LSK cells from 
our Flt3D835Y/+ and Flt3ITD/+ mice compared to wild type samples. The downregulation in the ITD 
mice is expected, since they exhibit a shift toward the myeloid lineage and a lack of lymphoid 
cells. Additionally, there is an obvious defect in DNA repair, so it follows that perhaps the 
downregulation of this protein contributes to faulty repair of double strand breaks and increased 




double strand breaks within non-lymphoid cell types that may be contributing to increased DNA 
damage seen in ITD bearing patients and knock-in mice. 
We also confirmed that Cox6a2 exhibited reciprocal expression in the two mutant 
models, with lower expression in the Flt3ITD/+ and higher expression in Flt3D835Y/+ compared to 
wild type. As a protein expressed in the mitochondrial membrane, Cox6a2 is a cytochrome c 
oxidase gene involved in the terminal steps of the electron transport chain, transferring electrons 
from reduced cytochrome c to oxygen. The observed down regulation with age in ITD mice 
indicates the loss of expression may be important in disease progression and development. The 
same cell population also exhibits and increase in reactive oxygen species with age. If membrane 
potential and permeability are compromised as a result of Cox6a2 repression, this may contribute 
to the increase in ROS accumulation, and DNA damage observed in these mice.  
 
5.2 Dnmt3a deletion cooperates with the Flt3-ITD mutation to drive leukemogenesis in a 
murine model  
With the advent of affordable whole genome sequencing, we have established an ever 
expanding compendium of leukemia associated mutations. The field is now faced with the 
arduous task of defining the functional contributions of these mutations, both in vitro and in 
vivo. FLT3-ITD and DNMT3A mutations frequently occur together in patients and portend a 
poor prognosis. While we have a knock-in model of the FLT3-ITD mutation, attempt to create a 
knock-in of the most frequent DNMT3A mutation (R882H) have been challenging (knowledge 
gained through personal communications with Tim Ley’s group). Since the most common 
R882H mutation is widely thought to behave in a dominant negative manner, bone marrow 




Chapter 3 defines, for the first time, a model of cooperativity between Flt3ITD/+ and 
Dnmt3a deletion, wherein mice with both mutations exhibit shortened survival, and leukemia 
development in a proportion of mice. The fact that loss of just one Dnmt3a allele reduces 
survival dramatically compared with Flt3ITD/+ alone, and also leads to leukemia, illustrates the 
importance of stoichiometry of the protein within the cell. We also determined the importance of 
both mutations in expanding the stem cell pool, and preliminary results suggesting that both are 
important in enhancing stemness via clonogenicity assays. While we used a modified Flt3ITD/+ 
mouse, where expression of the mutant allele was repressed, then restored simultaneously with 
Dnmt3a deletion, this still doesn’t perfectly model the order of events in clonal evolution in 
human samples (Shlush,L.I. 2014; Welch,J.S. 2012). The ideal model would elicit expression of 
the mutant Dnmt3a allele first (rather than a knock-out), then induce expression of Flt3-ITD. 
These mice would more accurately mimic the step wise progression of mutations we know to 
occur through sequencing studies, however no such model currently exists.  
5.3 Addition of mutant NPM1 increases disease aggressiveness in Flt3ITD/+;Dnmt3af/f  
mice 
The work presented in chapter 4 is extremely preliminary, but aims to answer a very 
important question. The recent TCGA report identified a new subset of leukemia patients that 
harbored DNMT3A, FLT3, and NPM1 mutations simultaneously. While I was already working 
on the project discussed in chapter 3, I was breeding in the NPMc+ transgene. After about a year, 
I finally had mice that were suitable for experiments, harboring the NPMc+ transgene, the Mx1-
Cre transgene, the Flt3-ITD, and wild type, one, or two floxed Dnmt3a alleles. Preliminary data 
suggests that mutant NPM1 in the context of the Flt3ITD/+;Dnmt3af/f   mice does increase disease 




While the decrease is not significant, it is extremely predictable at about 150 days. This work is 
ongoing to include many more mice and additional genotypes. 
5.4 Additional opportunities on the horizon 
The wealth of publicly available data has increased dramatically during my training, and 
serves as a rich resource to draw conclusions from mouse studies, and inform future experiments. 
The ultimate goal of each chapter presented in this dissertation is to functionally characterize the 
contributions of each common leukemia associated mutation in a genetically pure system. By 
perturbing the endogenous mouse locus of a given gene, we can study how that one gene, in 
isolation, contributes to cellular and disease phenotypes.  
Given the long lag time to disease development in Flt3ITD/+;Dnmt3af/f  mice from chapter 
3, for example, there are likely a number of cooperating genetic events that must occur during 
disease progression to finally result in transformation. One of our future goals is to perform 
exome sequencing to define somatic changes that may be common among these mice (or fall into 
common pathways).  
More immediately, we aim to take LSK cells from wild type, Dnmt3af/f, Flt3ITD/+, and 
Flt3ITD/+;Dnmt3af/f   at 100 days post pIpC injection and perform MBD-seq (or RRBS as funds 
dictate) and RNA-Seq to look at the changes each genetic abnormality is responsible for. By 
using the LSK population at a time point prior to leukemia development, we can compare 
between genotypes, as Flt3ITD/+ mice never exhibit leukemia. We will not only be able to 
correlate expression changes with epigenetic modifications, but we will also be able to use these 
data as a powerful resource to discover “essential” or targetable genes. For example, recently, 




performed bisulfite sequencing and gene expression analysis (Shih,A.H. 2015). They saw that 
Gata2 was hypermethylated and downregulated in double mutant mouse samples, as well as 
patients with both mutations as analyzed through public data and independent sequencing efforts. 
By transducing Flt3ITD/+;Tet2-/- bone marrow with Gata2, they found re-expression of Gata2 
enforced differentiation and attenuated disease. These findings indicate that Gata2 silencing is an 
important event in disease progression, and perhaps reactivating the gene therapeutically would 
be effective in treating AML. We hope to implore a similar strategy with our Flt3ITD/+;Dnmt3af/f 
samples and identify similarities between mouse and human commutated samples that may 
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Appendix 1. R code for expression analysis in chapter 2 
> library(limma) 
> x <- read.ilmn(files="probe new.txt",ctrlfiles="control probe 
new.txt",other.columns="Detection") 
Reading file probe new.txt ... ... 
Reading file control probe new.txt ... ... 
> options(digits=3) 
> targets <- readTargets("targets.txt") 
> y <- neqc(x) 
> y <- y[expressed,] 
> ct <- factor(targets$gtype) 
> design <- model.matrix(~0+ct) 
> colnames(design) <- levels(ct) 
> fit <- lmFit(y,design) 
> contrasts <- makeContrasts(D835Y-WT, ITD-WT,levels=design) 
> contrasts.fit <- eBayes(contrasts.fit(fit, contrasts)) 
> summary(decideTests(contrasts.fit, method="global")) 
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